Segment Information (Tables)

6 Months Ended

Jun. 30, 2026

Summary Of Disaggregated Research And Development Expenses

In addition to the significant expense categories included within net income presented on the Company's statements of operations and comprehensive loss, see below for disaggregated research and development expenses:


	Three Months Ended
	June 30, 2026		March 31, 2026
External clinical development expenses(1):
Darovasertib	$	32,123	$	23,332
IDE397		2,893		3,515
IDE161		1,976		1,607
IDE849		7,397		4,765
IDE892		3,982		2,180
IDE034		3,205		6,808
IDE574		3,222		3,052
Personnel related and stock-based compensation		21,848		20,072
Other research and development expenses(2)		32,043		30,395
Total research and development expenses	$	108,689	$	95,726


	Six Months Ended
	June 30, 2026		June 30, 2025
External clinical development expenses(1):
Darovasertib	$	55,456	$	48,109
IDE397		6,407		7,531
IDE161		3,583		4,016
IDE849		12,162		685
IDE892		6,162		2,020
IDE034		10,013		106
IDE574		6,274		1,253
Personnel related and stock-based compensation		41,920		33,015
Other research and development expenses(2)		62,438		48,377
Total research and development expenses	$	204,415	$	145,112

(1) External clinical development expenses include manufacturing and clinical trial costs. These expenses are primarily for services provided by external consultants, CMOs (“Contract Manufacturing Organizations”) and CROs (“Contract Research Organizations”).

(2) Other research and development expenses include manufacturing and clinical trial costs for preclinical and earlier clinical stage programs. These expenses are primarily for services provided by external consultants, CMOs and CROs.